Abstract Library

#3533 Identification of proangiogenic plasmatic biomarkers in patients with advanced grade 1/2 pancreatic (pan) and gastrointestinal (gi) neuroendocrine tumors (NETs) treated with Lenvatinib: A subanalysis from the TALENT phase II clinical trial

Introduction: TALENT phase II trial provided evidence of the efficacy of Lenvatinib in patients with panNETs and giNETs. However, no predictive biomarker has been associated to antiangiogenic treatment benefit to date.

Conference:

Presenting Author: Garcia-Alvarez A

Authors: Garcia Alvarez A, Hernando J, Jimenez-Valero G, Martinez A, Fazio N,

Keywords: Lenvatinib, Angiogenesis, Ang2, VEGFR2,

#3483 A phase II single arm interventional trial evaluating the activity and safety of combination between CABOzantinib and TEMozolomide (TMZ) in lung and GEP-NENs progressive after SSAs, everolimus, sunitinib or PRRT-CABOTEM

Introduction: Cabozantinib (Cbz), a tyrosine kinase inhibitor, and Temozolomide (TMZ), an alkylating agent, show relevant clinical implications in neuroendocrine neoplasms (NENS). In glioma patients, the combination of Cbz and TMZ was well tolerated even with the addition of radiotherapy. It is possible to hypothesize a synergistic combination of Cbz and TMZ. Cbz, through the inhibition of the c-MET pathway, could enhance the sensitivity of NENs to TMZ. In addition, the intermittent metronomic schedule of TMZ has a proven anti-angiogenic activity that could be additive and/or enhance the anti-angiogenic effect of Cbz.

Conference:

Presenting Author:

Authors: Clemente O, Starita N, Cives M, Bracigliano A, Badalamenti G,

Keywords: neuroendocrine, Cabozantinb, Temozolomide, treatment, clinical trial, NEN,

#2168 Phase II Trial of Cabozantinib in Patients with Carcinoid and Pancreatic Neuroendocrine Tumors

Introduction: Activation of VEGFR2 and MET is implicated in driving growth of NET. Cabozantinib inhibits VEGFR2, MET, AXL, RET.

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author:

Authors: Chan J, Faris J, Murphy J, Blaszkowsky L, McCleary N,

Keywords: cabozantinib, pancreatic neuroendocrine tumor, carcinoid, phase II,

#1374 The Usefulness of Assessment the Serum Concentrations of Vascular Endothelial Growth Factor (VEGF) and Its Soluble Receptor Type 2 (VEGFR2) in Patients with Neuroendocrine Neoplasm (NEN)

Introduction: Angiogenesis plays an important role in tumour growth and disease progression. VEGF is a angiogenesis-stimulating factor. VEGFR2 has antiangiogenic properties.

Conference: 13th Annual ENETSConcerence (2016)

Presenting Author:

Authors: Rosiek V, Kos-Kudła B, Zemczak A,

Keywords: neuroendocrine neoplasms, VEGF, VEGFR2,

#1249 Impact of VEGF and VEGFR Polymorphisms on Neuroendocrine Tumors of the Gastro-Entero-Pancreatic System (GEP-NET) Outcome.

Introduction: Improving our understanding of the molecular biology of GEP-NETs represents a key challenge in the treatment of these rare tumors.

Conference: 12th Annual ENETSConcerence (2015)

Presenting Author: Berardi R

Authors: Berardi R, Pagliaretta S, Rinaldi S, Morgese F, Partelli S,

Keywords: Angiogenesis, Prognosis, Neuroendocrine tumors,